Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Items 1,801–1,900 of 2,053
Dimnjaković, J., Buble, T., & Brborović, O. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1760695
“Davies et al. fi nd GLP-1 agonists to be bene fi cial for MACE and neutral toward heart failure (42).”
InfluentialSachin, Kriplani, P., Dass, R., Malhotra, H., & Arora, D. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10597-9
Saab, C., Mansour, A. A., Rahmah, A. M., Al-Attar, D. M. R. A., Alrubaye, H. F., Alidrisi, H. A., Nwayyir, H. A., Khudhair, M. S., Ahmed, M. J., AL-Ibrahimi, S. M., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01861-9
“This tailored approach aims to optimize both glycemic outcomes and long‑term organ protection while considering practical implementation challenges [7, 9].”
JENDLE, J. H., Adolfsson, P., Hellman, J., Klanger, B., & Ekberg, N. R. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261442987
“3,37 A comparison of the policy landscapes across a range of European countries further highlights the limited access to CGM for people with insulin-treated T2DM in Sweden.”
Obesity and Diabetes: A Complex Connection
Chandrasekaran, S. (2026) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000001017
Natarajan, K., Clerman, A., Soosaar, J., Sye, S., Giacomini, J., Conti, D. S., Bhalodia, A., Flint, J., Chattopadhyay, S., Hartka, K., et al. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70295
Alawadi, F., Abdelgadir, E., Hassoun, A. A. K., Abusnana, S., Afandi, B. O., Aldahmani, K. M., Alkaabi, J., Bashier, A. M., Bayado, F., Belaila, B. A. B., et al. (2026) · Dubai Diabetes and Endocrinology Journal · doi:10.18502/ddej.v32i1.21067
The significant role of gliflozins in the treatment of type 2 diabetes mellitus
Kolesárová, M., Bučková, M., Marcinčáková, D., Mačeková, Z., & Takáč, P. (2026) · Klinická farmakologie a farmacie · doi:10.36290/far.2025.072
Alharbi, A., Lammila-Escalera, E., Hayhoe, B. W. J., Aldakhil, R., Majeed, A., El-Osta, A. A. R., & Neves, A. L. (2026) · JMIR Formative Research · doi:10.2196/89898
“Effective diabetes management relies on sustained self-management, primarily the regular monitoring of blood glucose levels [6].”
Chen, L., Liu, H., Chen, Y., Xiao, Q., Huang, Z., Li, Z., Zhang, X., Fan, X., Xiao, M., Li, X., et al. (2026) · Food & Function · doi:10.1039/d5fo04996b
Talyshinskii, A., Gauhar, V., Yuen, S. K. K., Güven, S., Tokas, T., Tsaturyan, A., Enikeev, D. V., & Somani, B. K. (2026) · Asian journal of urology · doi:10.1016/j.ajur.2025.11.004
“They are known for their ability to lower blood glucose and are used in cardiology and nephrology to treat heart failure and chronic kidney disease (CKD) [6].”
Papakitsou, I., Papazachariou, A., & Filippatos, T. D. (2026) · World Journal of Clinical Cases · doi:10.12998/wjcc.v14.i14.120574 · Cited by 1
Lin, S., Chen, J., Hsiao, C.-C., Fang, Y., Chen, M., Tsai, M., & Yang, H. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70276 · Cited by 1
Oshakbayev, K., Nabiyev, A., Durmanova, A., Kuttymuratov, G., Suleimenov, T., Bikhanov, N., Idrisov, A., Bazheneyeva, G. Z., Manekenova, K., Akilzhanova, A. R., et al. (2026) · Nutrients · doi:10.3390/nu18091382 · Cited by 1
“GLP-1 receptor agonists and GIP/GLP-1 agonists demonstrate significant weight loss, simultaneous improvements in blood pressure and blood sugar, and a reduction in cardiovascular events [89,153].”
Lu, C.-H., Ch, C., Ou, H., Tseng, Y.-H., Wu, C., Jiang, J.-Y., Tu, S., Yang, Y., Tsai, M.-T., & Wang, C. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.04.012 · Cited by 1
DPP-4 inhibitors in current diabetes care: their foundational role in treating to target
Avogaro, A., Fiaccadori, E., & Rizzo, M. R. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113288 · Cited by 1
Zalesiak, M., Caspar, K., Mocek, A., et al. (2026) · Diabetologie und Stoffwechsel · doi:10.1055/s-0046-1820042
Sahay, R. K., Gowda, A., Singh, M. K., Rao, A. G., Duraisamy, R., Gangwani, D., Shukla, J., Agarwal, V., Patil, S. S., Ambrish, C., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70778
Škudar, S. (2026) · Cureus · doi:10.7759/cureus.108113
“Importantly, contemporary guidelines from the American Diabetes Association emphasize the need to individualize glycemic targets and treatment strategies, particularly in patients with comorbidities and cognitive impairment [10].”
Shah, J., Mahajan, A., & Muley, A. (2026) · Precision Nutrition · doi:10.1097/pn9.0000000000000136
Knupp, J., Hill, A., Thomas, N. J., McDonald, T. J., Young, K. G., Fraser, D. P., Hattersley, A. T., McKinley, T. J., Shields, B. M., & Jones, A. G. (2026) · medRxiv · doi:10.64898/2026.05.01.26352217 · Cited by 1
Yogeshappa, V. G., Avacharmal, R., Soni, M., Nandan, D., Nair, R., & Maduranga, M. W. P. (2026) · International Conference on Image Processing and Robotics (ICIPRoB) · doi:10.1109/iciprob69625.2026.11497811 · Cited by 3
“(4) It operationalizes the concept of community of practice to demonstrate how the community’s social interactions strengthen individual behavioral change over time, thereby connecting peer support to enhanced clinical outcomes [7-9].”
Pollard, K. J., Ames, M. L., Anderson, K., Gobble, J. E., Moore, S., Patel, P. M., Pauly, K. R., Staffier, K. L., Tondapu, P., & Karlsen, M. C. (2026) · American Journal of Lifestyle Medicine · doi:10.1177/15598276261438370 · Cited by 1
Wearable Devices for Management of Chronic Diseases: Improving Patient Quality of Life and Outcomes
Ghozali, M. T. (2026) · Health informatics · doi:10.1007/978-3-032-23933-4_8
Eiswirth, M. E., Resl, M., Kulzer, B., Roos, T., Trümpy, C., Balmer, M. L., Witthauer, L., Mader, J. K., Diem, P., Heinemann, L., et al. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261444041
“6,7 Diabetes technology, such as systems for continuous glucose monitoring (CGM), insulin pumps, and automated insulin delivery (AID) systems can help improve glycemic control and alleviate the social and emotional burden of living with diabetes.”
Nakada, R., Lane, D. R., Iwata, S., Isogawa, A., Toyoda, M., Sawaki, H., Murata, T., Kajino, S., Waki, H., Kato, S., et al. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261445108
Teng, J., Li, T., Tan, Y., & Tang, H. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1775359
Thomsen, C. H. N., Cichosz, S. L., Kronborg, T., Hangaard, S., Vestergaard, P., Hirsch, I. B., Klonoff, D. C., & Jensen, M. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261441312
Tian, H.-Y., Xu, C., & Li, Y. Z. (2026) · Dermatologic Therapy · doi:10.1155/dth/8984260
An Introduction of Lifestyle Medicine
Tremewan, C., Ergun-Longmire, B., Patel, D. R., & Goetting, M. G. (2026) · Springer eBooks · doi:10.1007/978-3-032-19116-8_22
Mihich, A., Caranti, S., & Verna, R. (2026) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-026-01421-9
Yakushevskaya, O. V. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-075
Urbanovych, A. M., Sidelnyk, N. Y., & Lishchuk, O. (2026) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.22.3.2026.1717
Vincent, Y.-M., Kasbi, M., Saouli, R., Blanchard, C., & Boussageon, R. (2026) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.70457
Laine, M. A., Järveläinen, H., Vielma, M., Ollila, H., & Rautava, P. T. (2026) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2026.100318
Prasad, S., Ahuja, A., Sharma, S., Nagda, J., Agrawal, S., Parmar, V., & Vardhan, H. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00296-2
Young, K., McGovern, A. P., Hopkins, R., Jansz, T. T., Cardoso, P., Holman, R. R., Pearson, E. R., Hattersley, A. T., Jones, A. G., Docherty, K. F., et al. (2026) · Diabetes Care · doi:10.2337/dc25-2973 · Cited by 1
“This group of patients represent a significant and increasing population for whom current preventative guidance is largely based on ASCVD outcomes rather than heart failure, and E u r op e P M C F und e r s A u t ho r M a nu s c r i p t s E u r op e P M C F und e r s A u t ho r M a nu s c r i p t s is inconsistent acr…”
InfluentialKumar, D., Batra, J., Pandeya, A., et al. (2026) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-026-01423-7
TANG, W., & ZHANG, Z. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.19.726272
Drug Repurposing Strategies in the Era of Precision Oncology
Orhan, A. (2026) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-032-24071-2_14
Ihalapathirana, A., Lavikainen, P., Siirtola, P., Tamminen, S., Chandra, G., Laatikainen, T. K., Martikainen, J. A., & Röning, J. (2026) · AI · doi:10.3390/ai7060183
Rubin, M., Preziosa, P., Margoni, M., Storelli, L., Pagani, E., Valsasina, P., Albergoni, M., Moiola, L., Filippi, M., & Rocca, M. A. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13881-3 · Cited by 1
Lee, H. W., Kim, H. J., Park, J. S., Lee, J. H., Park, J. J., Gwon, M., Cho, J., Seong, S. J., & Yoon, Y. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s574016 · Cited by 1
Chang, A., Yang, T.-C., Chang, A., Hong, C., & Tai, Y. (2026) · Sage Open Chronic Disease · doi:10.1177/27558428261449950
Sydorenko, V., Karpenko, N. A., Ivanova, I., et al. (2026) · Biological Trace Element Research · doi:10.1007/s12011-026-05164-9
Qin, J., Tang, M., Wang, X., et al. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1787562
“…gain and lower hypoglycemia risk than intensified insulin regimens, and improved gastrointestinal tolerability relative to GLP-1 RA monotherapy (23). iGlarLixi has demonstrated significant reductions in HbA1c and mitigated insulin-associated weight gain without increasing hypoglycemia risk in…”
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2766-3375
Júnior, L. F., de Araújo, E. F., Pereira, A. C., & de Souza, A. M. L. B. (2026) · Revista Brasileira de Medicina de Família e Comunidade · doi:10.5712/rbmfc21(48)4875
Anatriello, A., Liguori, V., Pentella, C., Zinzi, A., Longo, M., Caruso, P., Maiorino, M. I., Esposito, K., & Capuano, A. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00864-4 · Cited by 1
Hakaste, L., Andersen, M. K., Ängquist, L. H., Maalmi, H., Vangipurapu, J., Özgümüş, T., Möllsten, A., Tavelin, B., Lehtovirta, M., Begum, M. C., et al. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101715
“Regarding fasting insulin resistance in Period 1–6 , the HOMA2-IR was significantly higher in all sub-groups compared to controls (Fig.”
InfluentialFąfara, M., Jeczkało, M., Kosiorowska, M., Kowalczyk, A., Lasoń, J., Makulska, M., Płachta, W., Sęk, W., Sieradzka, A., & Wegenko, C. M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5796
Permatasari, L., Andayani, T. M., & Rahmawati, F. (2026) · Journal of Pharmaceutical And Sciences · doi:10.36490/journal-jps.com.v9i2.1526 · Cited by 1
Milhm, G. P., Moreira, F. D. L., & Abrahim-Vieira, B. D. A. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00772
Metformina y su rol más allá del control glucémico: una revisión narrativa
Jiménez, J., & Palacios, M. (2026) · Anales de la Facultad de Ciencias Médicas (Asunción) · doi:10.18004/anales/2026.e59012670
Ehteshami, F., Verjans, A., Cassidy, R., Tediosi, F., Fink, G., & Munoz, D. C. (2026) · Public health reviews · doi:10.3389/phrs.2026.1608655
“The management of T2DM and HTN was defined as approaches that enable achieving and maintaining glycemic control and blood pressure levels, preventing or delaying complications, and enhancing quality of life [26, 27].”
TIRZEPATIDA E OS RISCOS DO USO SEM PRESCRIÇÃO MÉDICA
Silva, B. E., Alves, N. D., Francelino, J. D. S., Spaziani, A. O., Eleutério, B. M. G., da Silva, F. S., Gonzaga, D. M. I. D. S., & Franco, R. F. (2026) · Revista de Geopolítica · doi:10.56238/revgeov17n6-005 · Cited by 1
Ganidağlı, S., Akbaş, E. S., & Öztürk, Z. A. (2026) · Endocrine · doi:10.1007/s12020-026-04670-z
Sőth, S. T., Bagosi, Z., Farkas, A., Gasztonyi, B., & Bujtor, Z. (2026) · Magyar Belorvosi Archívum · doi:10.59063/mba.2026.79.2.2
Crabtree, T. S. J., Aldafas, R., Qureshi, N., Gordon, J. P., Vinogradova, Y., & Idris, I. (2026) · Age and Ageing · doi:10.1093/ageing/afag149
Ljungberg, C., Bonnesen, K., Schmidt, M. S., Vandenbroucke‐Grauls, C. M. J. E., Dalager‐Pedersen, M., Sørensen, H. T., Nørgaard, M., & Thomsen, R. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70937 · Cited by 1
Лагода, Д. (2026) · Здобутки клінічної і експериментальної медицини · doi:10.11603/1811-2471.2026.v.i2.16405
Matsushita, T., Wada, Y., Saburi, M., Kobayashi, K., Tsukamoto, S., Kawanami, D., Suzuki, D., Tsuriya, D., Wakui, H., Kanasaki, K., et al. (2026) · Hypertension Research · doi:10.1038/s41440-026-02695-5
“Switching to GLP-1RA or initiating combination therapy is considered when SGLT2 inhibitors are unavailable or when additional weight loss is desired [17, 18].”
Preoperative fasting for patients who take GLP-1 receptor agonists: should we Sip Til Send?
Lowes, L. (2026) · Advances in Perioperative Care · doi:10.14324/111.444/apoc.3777
Ulander, M., Agholme, J., Toll, E., Wijkman, M., & Iredahl, F. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.05.007
Koné, A., Mansaré, A., Dieng, K., Samoura, S., Moussa, S. N. L., Essaga, C. E., Bah, M. B., Barry, I. S., Diakité, S., Sylla, I. S., et al. (2026) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2026.166039
Lugo-Palacios, D. G., Bidulka, P., Charlton, P., Huston, B., Carnegie, A. C., Carroll, O., O’Neill, S., Adler, A., Basu, A., Silverwood, R. J., et al. (2025) · Health Technology Assessment · doi:10.3310/asdb8011
Suherman, L. P., Novalina, D., Kartidjo, P., et al. (2026) · Journal of Pharmaceutical And Sciences · doi:10.36490/journal-jps.com.v9i2.1501
“The progressive decline in pancreatic beta-cell function and high insulin resistance, which are frequently exacerbated by cardiovascular comorbidities such as hypertension, often render monotherapy insufficient [15].”
Zhang, Y., Nguyen, T., Shin, H., Al-Sabbah, S., Warner, L. C., Kang, J., & Hu, J. (2026) · Diabetology · doi:10.3390/diabetology7060109
Zou, H.-Y., Jiang, H., Xiao-di, G., Wen, Z.-Y., Shi, Y., Zhou, A.-D., Wang, M., Xu, F., & Cai, M. (2026) · World Journal of Diabetes · doi:10.4239/wjd.120343
Goyal, M. K., Hatwal, J., Desai, R., Sehgal, T., & Batta, A. (2026) · World Journal of Diabetes · doi:10.4239/wjd.115820 · Cited by 2
Badgandi, M., Srinath, A., Mandora, V., Kandar, D. K., Shukla, P., PUNATAR, D. H., Jain, V., Kumar, S., Girish, P., Budhwar, A., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_20_26
Geroprotective Agents, Including Glucagon-Like Peptide-1 Receptor Agonists, for Ocular Health
Nguyen, A., Zhu, A., & Khouri, A. S. (2026) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1177/10807683261456222
“31,34 Notably, in 2022, both GLP-1 RAs and SGLT-2i were incorporated into fi rst-line recommendations for patients with cardiorenal comorbidities.”
Semaglutide for Organ Protection
Kharb, S., Bhattacharjee, B., Karuppan, A., V, Khaire, S. S., Routray, P., Ganta, S., Pakhale, K., Pareek, R., Matta, R., Sabharwal, M., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_27_26
Chaulagain, S., pandey, M., Saurav, S., Malla, D., Agrawal, K., Khatiwada, S., Koirala, T. N., & Aushili, M. (2026) · Cureus · doi:10.7759/cureus.110712
“…years, newer classes of glucose-lowering agents, including sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA), have gained prominence due to their demonstrated cardiovascular (CV) and renal benefits in specific patient populations [6,7].”
Varghese, R. T., Ayar, U. D., Zamin, M., Oyalade, F., Valencia, V., & Aoun, M. L. (2026) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2026.06.011
Current trends in semaglutide therapy and strategies to improve its bioavailability
Nayak, S., Dessai, A. D., & Nayak, U. Y. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2688990 · Cited by 3
Adults with Type 1 Diabetes and Insulin-Requiring Type 2 Diabetes
Hormachea, S. (2026) · American Diabetes Association eBooks · doi:10.2337/9781580408493-ch06
Shen, J., Xu, X., Lin, Y., Zhang, H., & Chen, L. L. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08805-z
“…knowledge between perioperative management and chronic disease management pathways, advance the application of standardized metabolic indicators such as glycated hemoglobin as core tools for value assessment, and provide a common value evaluation framework for multidisciplinary collaboration [41].”
Sharma, B., Tripathi, P., KADAM, N. S., & GANLA, M. H. (2026) · Cureus · doi:10.7759/cureus.110884
Falih, I. Q., Najim, H. D., & Tahir, N. T. (2026) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2026.100317
Yin, Y., Ma, J. H., Liu, D., Duan, W., Cheng, Z., Jiang, H. X., Zhang, Y., Wu, G., Zhuang, H., Gu, W., et al. (2026) · Med · doi:10.1016/j.medj.2026.101183
Mian, M. H. S., Janahi, K. A. H. A., Tayeb, A., Musaffar, F. M. M., Khalil, N., Toubah, S. H. A., Karim, A. M. A., Almarzooqi, A. M., Sayfoo, F. M., Hamadeh, A., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01888-y
“Adverse outcomes from OAO and T2DM can be mitigated through effective multidisciplinary treatment using lifestyle interventions [9–11], medications [11], surgical options [12, 13], and, more recently, pharmacological interventions such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs)…”
InfluentialKardiometabolisches Syndrom – Pathophysiologie, Therapie und Prävention
Raeder, S. (2026) · Kardiologie up2date · doi:10.1055/a-2654-6802
“Erste Humanstudien zeigen eine Reduktion von TMAO sowie eine Verbesserung der Endothelfunktion; belastbare Daten zu”
Hinton, W., Joy, M., Forbes, A., Whyte, M., Ordóñez-Mena, J. M., Fan, X., Ferreira, F., Meza-Torres, B., Munro, N. M., de Lusignan, S., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70946
Correia, P. E., Teixeira, P. P., Martins, B. A. E. T., Porepp, O. D. S. C., Kunzler, L. B., da Natividade, G. R., Ferrari, G. T., Spiazzi, B. F., Colpani, V., & Gerchman, F. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.103411
Adhikary, R. K., Widyowati, R., Mondal, S., Kurnianingsih, Susanto, E., Septama, A. W., Effendi, W. I., Kamal, M. S., Hermanu, A. I., Darwin, P., et al. (2026) · Food and Humanity · doi:10.1016/j.foohum.2026.101315
Lavadinho, I. C. E., Calado, N., & Simões, J. A. (2026) · Diabetology · doi:10.3390/diabetology7060119
“…major organizations like the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend annual cognitive screening for patients with T2DM aged 65 and older [5,6], such assessments are frequently omitted in routine primary and specialized care.”
To Hold or Not to Hold, That Is the Question: Sick Day Medication Guidance as Routine Care
Thavarajah, S. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.01.019 · Cited by 1
Choe, H. J., Koo, B. K., Hong, Y., Kim, N. H., Moon, J. S., Lee, Y., Cho, H., Kwak, S. H., Lim, S. K., Kim, D.-L., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113388
Arteaga-Díaz, J. M., Torres-Grajales, J. L., Sauque‐Reyna, L., Salamanca‐Carrillo, C., & Anguiano, L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71018
“…(BI) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) for individuals failing to achieve their treatment goals with other therapies [1, 6]. iGlarLixi is a once-daily FRC therapy combining insulin glargine (iGlar; 100 U/mL) and lixisenatide (Lixi)—possessing complementary…”
Teli, B., Sathe, S., Kalra, R., Mahajan, V., Mehta, A., Shinde, R., Kunwar, B., Kahale, P., Sinkar, A., Palimkar, P., et al. (2026) · Cureus · doi:10.7759/cureus.111322
“…(EASO), American Association of Clinical Endocrinology (AACE), Obesity Canada, Kidney Disease: Improving Global Outcomes (KDIGO), iCARDiO, and American College of Cardiology (ACC)/American Heart Association (AHA), similarly recommend GLP-1RAs and semaglutide in appropriate populations [49-55].”
Liao, M., Wang, Q., An, D., Bao, M., Xiong, Y., Yang, K., & Chen, L. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.178690
Pippi, R., Prete, D., Fano, M. D., Fruttini, D., Caprai, M., Mele, M. P., Stabile, D., Torlone, E., Porcellati, F., Rinonapoli, G., et al. (2026) · Diabetology · doi:10.3390/diabetology7070120
“Leading scientific societies recommend that people with diabetes follow a balanced diet, engage in regular PA, replace sedentary time (ST) with PA whenever possible [10,11], and adopt healthy sleep habits [12].”
Lee, D. H., Kim, H. S., You, S., Bae, Y., Yoo, H., Jeong, B., Lee, S. W., Lee, Y. L., & Shin, W. (2026) · Scientific Reports · doi:10.1038/s41598-026-58787-2
Bruno, G. M., Valentino, M. C., Buda, S., et al. (2026) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2026.3790
“Prescribing patterns observed in the Post–Note 100 period appear to align with ADA/EASD (5) and KDIGO (11) recommendations: the use of metformin and sulfonylureas declined, DPP-4 inhibitors increased modestly, and GLP-1 receptor agonists and SGLT-2 inhibitors showed a marked increase, particularly among patients at hi…”
InfluentialShalbaf, N., & Khoshnevis, T. (2026) · Studies in Multidisciplinary Medical Research · doi:10.66224/smmr.202602.02.04
Zhao, C. (2026) · Pakistan Journal of Pharmaceutical Sciences · doi:10.36721/pjps.2026.39.9.243.1
Polonsky, W. H., Low, E., Dias-Barbosa, C., Clark, A., Bailey, K., Ilag, L., GONCALVES, L. F., Threlkeld, R. J., Child, C. J., Davidson, M. B., et al. (2026) · Patient · doi:10.1007/s40271-026-00829-y
Josefsson, C., Pöder, U., Hedström, M., & Olsson, E. M. G. (2026) · Value in Health Regional Issues · doi:10.1016/j.vhri.2026.101660
Guanoliquin, K. P. D. L. C., Juca, D. C. S., Alcocer, Y. P., & Cuadrado, S. P. A. (2026) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20262193
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.